JHD

Journal of Huntington’s Disease

ISSN print
1879-6397
ISSN online
1879-6400
Volume
3; 4 issues
Status
Last issue (3:2) online on 30 June 2014
Next issue
3:3 scheduled for September 2014
Back volumes
1-2
Subject
Biochemistry, Medicine & Health, Neurosciences, Neurosciences
Institutional subscription for 2014 €525 / US$720 Excluding VAT
Subscription Rates Free Sample Copy
Share this journal

Journal of Huntington’s Disease accepted for inclusion in PubMed (MEDLINE®)
We are proud to announce that the Journal of Huntington's Disease has been selected for inclusion in MEDLINE®, the largest component of PubMed. MEDLINE® is searchable for free using PubMed at pubmed.gov. Citations and abstracts for articles published in the Journal of Huntington's Disease going back to Volume 1/Number 1 are now available online.

New Sister Journal: Journal of Neuromuscular Diseases
JHD welcomes a new sister journal: Journal of Neuromuscular Diseases (JND), edited by Carsten G. Bönnemann and Hanns Lochmüller. Inaugural issue of JND is now freely available online. This journal is accepting papers.

JHD now has its own Facebook page at: www.facebook.com/journalhd. The JHD Facebook page is run by Dr. Joan Steffan. We invite you to Like JHD to receive automatic updates to your news overview whenever new information is posted.

The Journal of Huntington's Disease is an international multidisciplinary journal to facilitate progress in understanding the genetics, molecular correlates, pathogenesis, pharmacology, diagnosis and treatment of Huntington's disease and related disorders. The journal is dedicated to providing an open forum for original research in basic science, translational research and clinical medicine that will expedite our fundamental understanding and improve treatment of Huntington's disease and related disorders.

Editors-in-Chief

Blair R. Leavitt, MD
The University of British Columbia
Vancouver, BC, Canada
Email: b.leavitt@iospress.com

Leslie M. Thompson, PhD
University of California
Irvine, CA, USA
Email: l.thompson@iospress.com

Associate Editor for Reviews

Marian DiFiglia
Massachusetts General Hospital Charlestown, Boston, USA

Associate Editors

Jang-Ho Cha 
Merck, North Wales, USA

Alexandra Durr
Université Pierre et Marie Curie, Paris, France

Anthony Hannan
The University of Melbourne, Victoria, Australia

Doug Langbehn
University of Iowa Hospital & Clinic, Iowa, USA

Michael Levine
University of California, Los Angeles, USA

Paul Muchowski
Soteria Therapeutics, San Francisco, USA

Martha A. Nance 
Struthers Parkinson's Center, Golden Valley, USA

Raj Ratan
Burke Rehabilitation Hospital, White Plains, USA

Lynn Raymond
University of British Columbia, Vancouver, Canada

Ralf Reilmann
George-Huntington-Institute, Münster, Germany

Christopher A. Ross 
Johns Hopkins University, Baltimore, USA

Frédéric Saudou 
Institut Curie, Paris, France

Sarah Tabrizi
University College London, London, United Kingdom

Anne B. Young 
Massachusetts General Hospital, Boston, USA

Social Media Editor

Joan S. Steffan
University of California, Irvine, USA

Managing Editor

Bethany Kumar
Case Western Reserve University, Cleveland, USA
Email: jhd@iospress.com

Editorial Board

Nick Allen
Cardiff School of Biosciences, Cardiff, United Kingdom

Neil Aronin
University of Massachusetts Medical School, Worcester, USA

Elizabeth Aylward
University of Washington, Seattle, USA

Roger A. Barker
University of Cambridge, Cambridge, United Kingdom

Gillian P. Bates
Kings College London, London, United Kingdom

M. Flint Beal
Weill Medical College of Cornell University, New York, USA

Ilya Bezprozvanny
University of Texas Southwestern Medical School, Dallas, USA

Kevin M. Biglan
University of Rochester Medical Center, Rochester, USA

Juan Botas
Baylor College of Medicine, Houston, USA

Patrik Brundin
Van Andel Research Institute, Grand Rapids, USA

Jeff Carroll
Western Washington University, Bellingham, USA

Elena Cattaneo
Universita degli Studi di Milano, Milan, Italy

Marie-Francoise Chesselet
University of California, Los Angeles, USA

Andrew Churchyard
Calvary Health Care Bethlehem, Victoria, Australia

Jody Corey-Bloom
University of California, San Diego, USA

Merit Cudkowicz
Massachusetts General Hospital, Boston, USA

Beverly Davidson
The University of Iowa, Iowa City, USA

Ray Dorsey
Johns Hopkins Medical Institutions, Baltimore, USA

Stephen B. Dunnett
Cardiff School of Biosciences, Cardiff, United Kingdom

Lisa M. Ellerby
Buck Institute for Age Research, Novato, USA

Richard Faull
University of Auckland, Grafton, New Zealand

Andrew Feigin
The Feinstein Institute for Medical Research, Manhasset, USA

Joaquim Ferreira
Instituto de Farmacologia e Terapêutica Geral, Lisbon, Portugal

Steven Finkbeiner
University of California, San Francisco, USA

Nellie Georgiou-Karistianis
Monash University, Victoria, Australia

James F. Gusella
Massachusetts General Hospital, Boston, USA

Mark Guttman
Centre for Movement Disorders, Markham, USA

Michael Hayden
Centre for Molecular Medicine and Therapeutics, Vancouver, Canada

Steven M. Hersch
Massachusetts General Hospital, Boston, USA

David E. Housman
Koch Institute at MIT, Cambridge, USA

Robert E. Hughes
Buck Institute, Novato, USA

Carl D. Johnson
Hereditary Disease Foundation, Broadway, USA

Lesley Jones
Cardiff University School of Medicine, Cardiff, United Kingdom

Aleksey G. Kazantsev
Massachusetts General Hospital, Boston, USA

Ron R. Kopito
Stanford University School of Medicine, Stanford, USA

Dimitri Krainc
Massachusetts General Hospital, Boston, USA

G. Bernhard Landwehrmeyer
Universitätsklinik Ulm, Ulm, Germany

Albert La Spada
University of California, San Diego, USA

Ruth Luthi-Carter
University of Leicester, Leicester, United Kingdom

Marcy MacDonald
Massachusetts General Hospital, Boston, USA

J. Lawrence Marsh
University of California, Irvine, USA

Mark Mattson
NIA, NIH, Bethesda, USA

Diane Merry
Thomas Jefferson University, Pennsylvania, USA

Anne Messer
Wadsworth Center, Albany, USA

Jenny Morton
University of Cambridge, Cambridge, United Kingdom

Richard H. Myers
Boston University, Boston, USA

Nobuyuki Nukina
Riken Brain Science Institute, Saitama-ken, Japan

Paul H. Patterson
California Institute of Technology, Pasadena, USA

Jane S. Paulsen
University of Iowa, Iowa City, USA

Henry Paulson
University of Michigan Health System, Ann Arbor, USA

George Perry
University of Texas at San Antonio, San Antonio, USA

Asa Petersen
Lund University, Lund, Sweden

Kimberly Quaid
Indiana University, Indianapolis, USA

Laura Ranum
University of Florida, Gainesville, USA

Anton Reiner
The University of Tennessee Health Science Center, Memphis, USA

Raymund Roos
Leiden University Medical Center, Leiden, Netherlands

Diana Rosas
Massachusetts General Hospital, Boston, USA

Adam Rosenblatt
Virginia Commonwealth University Medical Center, Richmond, USA

Anne Rosser
Cardiff University, Cardiff, United Kingdom

Ira Shoulson 
Georgetown University, Washington DC, USA

Andrew Singleton
NIH, Bethesda, USA

Julie Stout
Monash University, Victoria, Australia

Ferdinando Squitieri
Neurological Research Institute IRCCS Neuromed, Pozzilli, Italy

Jean-Paul Vonsattel
Columbia University, New York, USA

Judith R. Walters
NIH, Bethesda, USA

Erich Wanker
Max Delbrueck Center for Molecular Medicine, Berlin, Germany

Alice Wexler
University of California, Los Angeles, USA

Nancy Wexler
Columbia University, New York, USA

Ed Wild
University College London, London, United Kingdom

X. William Yang
University of California, Los Angeles, USA

Scott Zeitlin
University of Virginia, Charlottesville, USA

SUBMISSION OF MANUSCRIPT

Authors are requested to submit their manuscript electronically to the journal’s editorial management system.

Note that the manuscript should be uploaded as one file with tables and figures included. This file can be a Word document, a PDF, or an embedded or zip file (.rar) if separate high resolution figures or a supplemental file such as a video are also to be included with the submission (the file size maximum for a video is 25MB). If the video is too large to submit, please contact jhd@iospress.com to arrange a file transfer. For further information about submitting supplementary data click here.

Resubmissions should include the manuscript number in the cover letter. Resubmissions should clearly mention that the submission is a Revision and include the reference number in the submission letter. The author's replies to the reviewer comments should be included in the revised manuscript itself (at the top). The revised paper should always be a Word document.

Submission of a Review paper should be clearly mentioned in the cover letter to help the editorial process.

Submission of an article is understood to imply that the article is original and unpublished and is not being considered for publication elsewhere. Any possible conflict of interest, financial or otherwise, related to the submitted work must be clearly indicated in the manuscript. Procedures involving experiments on human subjects should be in accord with the ethical standards of the Committee on Human Experimentation of the institution in which the experiments were done or in accord with the Helsinki Declaration of 1975. Procedures involving experimentation on animal subjects should be in accord with either the guide of the institution in which the experiments were done, or with the National Research Council’s guide for the care and use of laboratory animals.

If the address to which proofs should be sent is different from the correspondence address, authors are kindly requested to indicate this. Both the editor and the publisher should be informed of any changes in either or both of these addresses. Please also supply a direct telephone number and a fax number, if available.

PREPARATION OF MANUSCRIPTS

Research Reports

Organization and style of presentation
1. Manuscripts must be written in English. Authors whose native language is not English are recommended to seek the advice of a native English speaker, if possible, before submitting their manuscripts. You can also visit www.internationalscienceediting.com. International Science Editing offers a language and copyediting service to all scientists who want to publish their manuscript in scientific peer-reviewed periodicals and books.

2. Manuscripts should be double spaced throughout with wide margins (2.5cm or 1in), including the abstract and references. Every page of the manuscript, including the title page, references, tables, etc., should include a page number centered at the bottom.

3. Manuscripts should be organized in the following order with headings and subheadings typed on a separate line, without indentation.

Title page
- Title (should be clear, descriptive and concise)
- Full name(s) of author(s)
- Full affiliation(s). Delineate affiliations with lowercase letters.
- Present address of author(s), if different from affiliation
- Running title (45 characters or less, including spaces)
- Complete correspondence address, including telephone number, fax number and e-mail address

Leave the author information blank if double-blind peer review is wished for, but do include the information in the cover letter.

Abstract and Keywords
-The abstract for research papers should follow the "structured abstract" format:
BACKGROUND: 
OBJECTIVE:
METHODS: 
RESULTS:
CONCLUSIONS:
The abstract should try to be no longer than 250 words.
- For other papers such as Reviews, the abstract should be clear, descriptive, and self-explanatory, and no longer than 250 words.
- Include a list of 4-10 keywords. These keywords should be terms from the MeSH database.

Introduction

Materials and Methods

Results

Discussion

Acknowledgments including sources of support

Conflict of Interest
If there is no conflict of interest to declare, do still include this section and insert "The authors have no conflict of interest to report".

References
- Place citations as numbers in square brackets in the text. All publications cited in the text should be presented in a list of references following the text of the manuscript. Only articles published or accepted for publication should be listed in the reference list. Submitted articles can be listed in the text as (author(s), unpublished data).
- All authors should be listed in the reference list.
- References must be listed in Vancouver style:

[1] Rose ME, Huerbin MB, Melick J, Marion DW, Palmer AM, Schiding JK, Kochanek PM, Graham SH. Regulation of interstitial excitatory amino acid concentrations after cortical contusion injury. Brain Res. 2002; 935(12): 406-416.
[2] Murray PR, Rosenthal KS, Kobayashi GS, Pfaller MA. Medical microbiology. 4th ed. St. Louis: Mosby; 2002.
[3] Berkow R, Fletcher AJ, editors. The Merck manual of diagnosis and therapy. 16th ed. Rahway (NJ): Merck Research Laboratories; 1992.
[4] Meltzer PS, Kallioniemi A, Trent JM. Chromosome alterations in human solid tumors. In: Vogelstein B, Kinzler KW, editors. The genetic basis of human cancer. New York: McGrawHill; 2002. p. 93113.
[5] Canadian Cancer Society [homepage on the Internet]. Toronto: The Society; 2006 [updated 2006 May 12; cited 2006 Oct 17]. Available from: http://www.cancer.ca/.

Tables
- Number according to their sequence in the text. The text should include references to all tables.
- Provide each table on a separate page of the manuscript after the references.
- Include a brief and self-explanatory title with any explanations essential to the understanding of the table given in footnotes at the bottom of the table.
- Vertical lines should not be used to separate columns. Leave some extra space between the columns instead.

Figure Legends

Figures
-
Number the figures according to their sequence in the text. The text should include references to all figures.
- Figures should preferably be formatted in TIF or EPS format. JPG is also acceptable.
- Figures should be designed with the format of JHD in mind and preferable sized as they will appear when printed. A single column of the journal is 77mm and two columns are 165mm.
- Figures should be at 300 dpi or higher and be cropped to include the figure only (no blank space). CMYK is preferred for color figures.
- On figures where a scale is needed, use bar scales to avoid problems if the figure needs to be reduced.
- Each illustration should have a brief self-explanatory legend that should be typed separately from the figure in the section of the manuscript following the tables.
- Costs for color figures in the print version of the journal are as follows: 1 figure - 650 euro; 2 figures - 900 euro; 3 figures - 1050 euro; 4 figures - 1200 euro; 5 figures - 1350 euro. Cost for each additional color figure will be 150 euro. Color figures are free in the electronic version of the journal. You may opt to send in both black/white figures for print, and color figures for the online PDF (please adjust the figure legend appropriately).Text removed here.

Supplementary Data
Supplementary data can be submitted with the manuscript, inserted at the end of the document. Legends should be included for each item. Each supplementary item should not exceed the file size of 10MB. Supplemental videos can also be submitted (see top of page), and a title and legend should be included as Supplementary Material within the manuscript. Large datasets should be hosted on the author’s own or institute’s website or in an appropriate database.

Reviews
Reviews should be authoritative and topical and provide comprehensive and balanced coverage of a timely and/or controversial issue. Reviews should be prepared as detailed above for a Research Report, omitting Introduction through Discussion, and include a conclusion.

Short Communications
A short communication is an article of original scholarship of unusual interest of less than 1500 words (not including references). An abstract of 100 words or less should be included with no subdivison of text into sections. References should be formatted as above. A total of two tables and/or figures are allowed.

Hypotheses
A hypothesis article should be a balanced and insightful consideration of a topic with novel hypotheses well presented and supported. The article should be prepared as a Research Report but without Methods or Results sections.

Book Reviews
Book reviews should be 750 words or less and without sections. Suggestions can be proposed to the Editors-in-Chief.

Section: Controversies
This will be a section with Pro and Con commentaries on a specific topic of interest to the HD community. Each author will generate a short opinion piece which will have a maximum of 1000 to 2000 words (with one figure and max 15 references) to make the basic argument. Both sets of authors will receive a copy of both articles, and will be given two weeks to generate a short (200 word max.) rebuttal prior to publication. It is recommended that unsolicited authors email a proposal letter and formal academic outline of the discussion to the Editors (at jhd@iospress.com) to assess the topic, before submitting manuscripts.

Section: Correspondence
These are short letters to JHD that are either:

A). relating to a specific issue/case history in HD. Authors can submit commentaries or case reports of 1000 words or less for possible inclusion in the JHD. It is recommended that authors email a proposal letter and formal academic outline of the manuscript to the Editors (at jhd@iospress.com) to assess the topic, before submitting the full manuscript. Commentaries and case reports should include an abstract  (100 words max) but no other subdivisions, and should not include more than 15 references and one figure or table.

B). a response to a specific article published in JHD. Inclusion in JHD will be based on editorial decision and revision may be requested. Letters relating to a previous article will be shared with the authors of the original article for possible response prior to publication. Letters should not exceed 500 words (excluding references) and should not include more than 5 references and one figure or table. A letter can be signed by no more than three authors. Submit these to jhd@iospress.com.

REMEMBER TO INCLUDE

In cover letter:
-
Name, postal address, phone number, fax number and e-mail address of the corresponding author.
- Name of an Associate Editor with expertise in the area of the study (if no Associate Editor is suitable, the Editorial Office will handle the submission).
- Statement that all authors have contributed to the work, agree with the presented findings, and that the work has not been published before nor is being considered for publication in another journal.
- A list of at least 4-6 potential reviewers knowledgeable in the area of the study and potential reviewer conflicts.
- Statement that procedures involving experiments on human subjects are done in accord with the ethical standards of the Committee on Human Experimentation of the institution in which the experiments were done or in accord with the Helsinki Declaration of 1975.
- Statement that procedures involving experimentation on animal subjects are done in accord with either the guide of the institution in which the experiments were done, or with the National Research Council's guide for the care and use of laboratory animals.

In manuscript:
-
Compliance with guidelines on human experimentation as well as protocol approval by a local Institutional Review Board should be specified.
- Compliance with guidelines of animal experimentation as well as protocol approval by the Institutional Animal Care and Use Committee should be specified.
- Statement of all financial and material support for this research and any potential conflicts should also be clearly identified in the the acknowledgment and Conflict of Interest sections. If there is no Conflict-of-Interest then still add this statement.

Resubmissions
Resubmissions should include the manuscript number and a reference that the paper is a revision. The point-by-point response to the previous reviews should be included at the top of the manuscript. 

Financial Disclosure
All affiliations with or financial involvement (e.g., employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, royalties) with any organization or entity with a financial interest in or in financial competition with the subject matter or materials discussed in the manuscript are completely disclosed in the letter of submission.

All financial and material support for this research and work are clearly identified in the manuscript including listing of support specified in the letter of submission that might constitute or give the appearance of influencing the findings, based on the judgment of the Editor-in-Chief in consultation with the Associate Editor handling the review of the manuscript.

Policy regarding the NIH Public Access Policy mandate (PubMed Central)
IOS Press grants authors permission to supply their own version of the article (not the published PDF version) to PubMed Central, at no charge.

Alternatively, the author can submit the final published version of the article, which can be ordered from IOS Press. This service costs US$120 / €100 and an order form will be sent with the galley proof of the article to the corresponding author.

Orders for a pdf of published articles can also be sent to order@iospress.nl.

Authors who have paid the Article Processing Charges (ACPs) for Open Access may freely deposit the final pdf.

The guidelines for PubMed Central submission can be found here. Submission Method C.

This policy is also applicable to European Pubmed Central submissions.

PRE-PRESS AND PROOFS

Accepted articles will be placed online as "pre-press" articles shortly after acceptance. This process will occur before the author receives proofs. The pre-press file will remain as the uncorrected proof version until the article is published in an issue and the final published version replaces the pre-press file.

The corresponding author will receive a pdf proof and is asked to check this proof carefully (the publisher will execute a cursory check only). Corrections other than printer's errors, however, should be avoided. Costs arising from such corrections will be charged to the authors.

OPEN ACCESS OPTION

The IOS Press Open Library® offers authors an Open Access (OA) option. By selecting the OA option, the article will be freely available from the moment it is published, also in the pre-press module. In the Open Library® the article processing charges are paid in the form of an Open Access Fee. Authors will receive an Open Access Order Form upon acceptance of their article. Open Access is entirely optional. See also our website for more information about this option IOS Press Open Library®.

COPYRIGHT

Copyright of your article
Authors submitting a manuscript do so on the understanding that they have read and agreed to the terms of the IOS Press Author Copyright Agreement.

Quoting from other publications
An author, when quoting from someone else's work or when considering reproducing figures or table from a book or journal article, should make sure that he is not infringing a copyright. Although in general an author may quote from other published works, he should obtain permission from the holder of the copyright if he wishes to make substantial extracts or to reproduce tables, plates or other figures. If the copyright holder is not the author of the quoted or reproduced material, it is recommended that the permission of the author should also be sought. Material in unpublished letters and manuscripts is also protected and must not be published unless permission has been obtained. Submission of a paper will be interpreted as a statement that the author has obtained all the necessary permission. A suitable acknowledgement of any borrowed material must always be made.

COMPLIMENTARY COPY AND PURCHASE

Complimentary copy
The corresponding author of a contribution to the journal is entitled to receive 1 author’s copy of the pdf free of charge, unless otherwise stated. Free copies will not be provided for conference proceedings and abstract issues.

How to order reprints, a pdf file, journals, or IOS Press books
An order form for reprints, additional journal copies or a non-watermarked pdf file will be provided along with the pdf proof.
If you wish to order reprints of an earlier published article, please contact the publisher for a quotation. IOS Press, Fax: +31 20 6870039. Email: editorial@iospress.nl.

An author is entitled to 25 % discount on IOS Press books. See Author's Discount (25%) on all IOS Press book publications.

Chemical Abstracts Service (CAS)
MEDLINE
Pubmed
PubsHub

2014 Neuroscience Neurology Brochure

31 Jan 2014 - Download the 2014 Neuroscience Neurology Brochure here. ...

Antisense Oligoneucleotide Corrects Striatal Transcriptional Abnormalities and Protects Function in HD Mice

26 Aug 2013 - Findings from postmortem studies of the brains of Huntington’s Disease (HD) patients suggest that transcriptional dysregulation may be an early step in the pathogenesis of HD before symptoms appear. Other studies report transcriptional alterations in the brains of some mouse models of HD. A new study has found transcriptional changes in mouse striatum which correlate with progressive motor and psychiatric deficits and, most importantly, reports for the first time, that an antisense oligonucleotide (ASO) may be used therapeutically to both correct striatal transcriptional abnormalities and improve motor and behavioral problems. The article is published in the latest issue of the Journal of Huntington’s Disease. ...

Leading Researchers Report on the Elusive Search for Biomarkers in Huntington’s Disease

21 May 2013 - While Huntington’s disease (HD) is currently incurable, the HD research community anticipates that new disease-modifying therapies in development may slow or minimize disease progression. The success of HD research depends upon the identification of reliable and sensitive biomarkers to track disease and evaluate therapies, and these biomarkers may eventually be used as outcome measures in clinical trials. Biomarkers could be especially helpful to monitor changes during the time prior to diagnosis and appearance of overt symptomatology. Three reports in the current issue of the Journal of Huntington’s Disease explore the potential of neuroimaging, proteomic analysis of brain tissue, and plasma inflammatory markers as biomarkers for Huntington’s disease....

Large Animal Models of Huntington’s Disease Offer New and Promising Research Options

23 Apr 2013 - Scientific progress in Huntington’s disease (HD) relies upon the availability of appropriate animal models that enable insights into the disease’s genetics and/or pathophysiology. Large animal models, such as domesticated farm animals, offer some distinct advantages over rodent models, including a larger brain that is amenable to imaging and intracerebral therapy, longer lifespan, and a more human-like neuro-architecture. Three articles in the latest issue of the Journal of Huntington’s Disease discuss the potential benefits of using large animal models in HD research and the implications for the development of gene therapy....

Cell Loss in the Brain Relates to Variations in Individual Symptoms in Huntington’s Disease

07 Jan 2013 - Scientists have wrestled to understand why Huntington’s disease, which is caused by a single gene mutation, can produce such variable symptoms. An authoritative review by a group of leading experts summarizes the progress relating cell loss in the striatum and cerebral cortex to symptom profile in Huntington’s disease, suggesting a possible direction for developing targeted therapies. The article is published in the latest issue of the Journal of Huntington’s Disease. ...

2013 Neuroscience Neurology Brochure

27 Nov 2012 - Download the 2013 Neuroscience Neurology Brochure here. ...

Well-known Author and Historian Reports on Progress in Huntington’s Therapies

26 Jun 2012 - Our understanding of the causes and mechanisms of Huntington’s disease (HD) has grown at a dramatic pace since the discovery of the genetic marker for the disease in 1983. While therapies to treat the disease lag behind these laboratory discoveries, disease altering interventions are moving closer to the clinic. In the inaugural issue of the Journal of Huntington’s Disease Alice Wexler, PhD, an authority on the history of Huntington’s disease, author, and research scholar with the UCLA Center for the Study of Women, recounts important milestones along the journey towards a treatment or cure for the disease....

Device Implanted in Brain Has Therapeutic Potential for Huntington’s Disease

19 Jun 2012 - Studies suggest that neurotrophic factors, which play a role in the development and survival of neurons, have significant therapeutic and restorative potential for neurologic diseases such as Huntington’s disease. However, clinical applications are limited because these proteins cannot easily cross the blood brain barrier, have a short half-life, and cause serious side effects. Now, a group of scientists has successfully treated neurological symptoms in laboratory rats by implanting a device to deliver a genetically engineered neurotrophic factor directly to the brain. They report on their results in the latest issue of Restorative Neurology and Neuroscience. ...

New Studies Hint at Possible Approaches to Protect Those at Risk for Huntington’s Disease

19 Jun 2012 - Two new studies published in the inaugural issue of the Journal of Huntington's Disease hint at possible approaches to protect those at risk for HD....